By my calcs cash is at about $25M as of 6/30 and burning $25M/year, so not too decent since the last thing they'd want is to let cash dwindle down and have no leverage with investors. I assume the prior PIPE buyers will reup again and squeeze them some more.
A CR in pancreatic would be very unusual but it's just one. They have a long way to go.
Market Data 
Markets 
AI
